Alphabet’s Secret Investments: Figma, BridgeBio & More Revealed
Alphabet’s strategic investments through its venture arms, GV and CapitalG, are expanding beyond its dominant search engine market and cloud computing presence. Recent 13F-HR filings reveal a diverse portfolio of 37 publicly traded stocks valued between $2.5 billion and $3 billion, with a significant emphasis on the healthcare and biotechnology sectors. This “secret” portfolio demonstrates a calculated approach to diversification and exploration of emerging technologies. Notable holdings include Planet Labs, a satellite imagery company valued at approximately $438 million, Figma, a cloud-based design collaboration platform, and BridgeBio Oncology Therapeutics.
Alphabet’s venture capital arms, GV and CapitalG, are actively reshaping the company’s investment landscape. While Google Search and Google Cloud continue to be key revenue drivers, the firm’s diversification strategy through these arms illuminates a forward-thinking approach. The portfolio currently comprises 37 publicly traded stocks, offering exposure to a range of sectors including healthcare, technology, and artificial intelligence. The total value of this portfolio sits between $2.5 billion and $3 billion, a testament to Alphabet’s commitment to innovation and expansion. This strategic shift underlines a desire to tap into high-growth potential areas rather than solely relying on its core business lines.
Several of Alphabet’s recent investments warrant particular attention. Planet Labs, with a $438 million holding, represents a strategic move into Earth observation technology, leveraging satellite imagery for diverse applications. Figma, a prominent player in the cloud-based design ecosystem, aligns with Google’s internal need for refined user interfaces across its products—Android, Chrome, and Workspace. The company’s recent public offering at $33 per share, currently trading around $38.50, presents an intriguing opportunity, although competition from Adobe’s XD and potential economic headwinds pose risks. Alphabet possesses over 215,500 shares of the company, valued at approximately $8.3 million.
BridgeBio Oncology Therapeutics, a biotechnology firm focused on targeted therapies for cancers like prostate and lung cancer, represents a more concentrated investment. Spin-off from BridgeBio Pharma, the company prioritizes precision medicine with lead candidates undergoing clinical trials. Alphabet’s interest aligns with its broader healthcare initiatives, demonstrated through ventures like Verily and its growing exploration of AI applications in drug discovery and genomics. Currently holding over 2.8 million shares valued at more than $37 million at a price of $13 per share, the company’s success hinges on positive trial outcomes and the ongoing demand for advanced cancer treatments within the $250 billion oncology market. The volatile biotech sector requires cautious consideration for investors.
Beyond financial investments, a crucial shift is occurring in retirement planning. Traditional approaches—solely focusing on stock picks or ETFs—are increasingly being questioned. The fundamental distinction lies between accumulation and distribution phases, prompting many to reconsider their retirement strategies. Millions are realizing they can retire earlier than anticipated by optimizing their savings and investment choices. The core difference stems from the changing dynamics between generating income and managing withdrawals. Discovering the three key questions that are causing many Americans to rethink their retirement plans can lead to a more informed and effective approach.
